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Background
The relationship between Helicobacter pylori (H. pylori) infection and chronic idiopathic 
thrombocytopenic purpura (ITP) has been confirmed; however, no clear evidence for the 
effectiveness of H. pylori eradication on ITP exists thus far. The purpose of this study was 
to investigate platelet recovery in chronic ITP after H. pylori eradication. 
Methods
A total of 25 patients (18 male, 7 female; the median age of 55 years) diagnosed with ITP, 
whose platelet counts were less than 100×10
3/μL, were enrolled. They were tested for 
H. pylori infection by the rapid urea test or urea breath test. All patients received triple 
therapy for 7 or 14 days to eradicate H. pylori infection. 
Results
Of the 25 patients, 23 (92%) were diagnosed with H. pylori infection. Of all the ITP patients, 
11 (44%) exhibited a complete response (CR) to H. pylori eradication therapy; 6 (24%), 
a partial response (PR); and 8 (32%) were nonresponsive (NR). Predictive factors of re-
sponse after H. pylori eradication therapy were platelet counts at the initial response 
(27.3% responders among patients with platelet counts ＜100×10
3/μL vs 100% res-
ponders among patients with platelet counts ≥100×10
3/μL, P＜0.001) and H. pylori in-
fectivity (73.9% responders among the H. pylori positive patients vs 0% responders among 
the H. pylori negative patients, P=0.032).
Conclusion
This study confirmed the efficacy of H. pylori eradication in increasing the platelet count 
in ITP patients. Further studies with a larger number of patients are necessary to identify 
the crucial predictive factors responsible for platelet recovery in chronic ITP patients with 
the H. pylori infection.
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INTRODUCTION
Helicobacter pylori (H. pylori) is a gram-negative micro-
aerophilic bacterium that colonizes the stomachs of over 
half the human population. H. pylori is the predominant 
agent of active chronic gastritis and gastric and duodenal 
ulcers. H. pylori is a cofactor in the development of both 
gastric adenocarcinoma and mucosa-associated lymphoid tis-
sue lymphoma. Recently, H. pylori has been implicated in 
various autoimmune disorders, including pernicious anemia 
and idiopathic thrombocytopenic purpura (ITP) [1, 2]. The 
prevalence of H. pylori infection in adult ITP patients is 
22% in the North American Caucasian population, 29% in 
the white French population; furthermore, it is nearly 50% 
i n  I t a l y ,  g r e a t e r  t h a n  7 0 %  i n  J a p a n ,  9 0 . 6 %  i n  C o l o m b i a .  
In South Korean adults, the prevalence was 64.7% in 1998 
and 59.9% in 2005 [2-7].
H. pylori infection is driven by urease, flagella, and 
adhesions. Virulence factors such as CagA and VacA play 
roles in colonization and infection. Other virulence factors 
are H. pylori neutrophil-activating protein (HP-NAP) and 
cell-wall lipopolysaccharide (LPS) [8-10]. The role of H. 
pylori in the development of ITP is not yet known. Many 
hypotheses have been proposed to address the mechanisms 
by which H. pylori causes ITP. Platelet-associated im-Korean J Hematol 2010;45:127-32.
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Table 1. Patients characteristics.
Characteristics
Age, years
Median (range)  55 (35-76)
Sex (%)
Male 
Female
18 (72.0)
7 (28.0)
H. pylori infectivity (%)
Positive
Negative
23 (92.0)
2 (8.0)
Disease duration before  H. pylori 
eradication, months
Median (range) 2.533 (0.0-27.07)
Number of previous treatment (%)
0
1
2
23 (92.0)
0
2 (8.0)
Duration of eradication therapy (%)
7 days
14 days 
21 (68.0)
4 (16.0)
Underlying condition (%)
Ulcer existence
Existence of hepatitis virus
Lymphoma
18 (72.0)
16 (64.0)
2 (8.0)
Follow-up duration, months
Median (range) 57.57 (4.53-123.53)
The values represent either the number (percentage) or the median
(range). 
Abbreviations: H. pylori, Helicobacter pylori; Follow-up duration, 
from diagnosis of ITP to last follow-up date.
munoglobulin G, CagA, LPS etc., have all been reported 
to play a role in platelet apoptosis [11, 12].
Until now, there have been many studies on the relation-
ship between H. pylori infection and ITP. Some studies have 
reported increased the platelet counts subsequent to the erad-
ication of infection [13-17], whereas others have failed to 
demonstrate the same beneficial effects [18-20]. 
In this retrospective study of patients with chronic ITP 
and H. pylori infection, we assessed the efficacy of H. pylori 
eradication in the restoration of platelet count and identified 
predictive factors associated with the therapeutic response. 
MATERIALS AND METHODS
1. Patients
The medical records of 25 adult chronic ITP patients, 
seen at Kosin University Gospel Hospital in Busan, South 
Korea, between June 1996 and November 2009, were retro-
spectively examined for the presence of gastric H. pylori 
infection. The diagnosis of ITP was made according to the 
criteria set by the American Society of Hematology (ASH) 
guidelines [21] based on thrombocytopenia (platelet count 
of less than 100×10
3/μL). Cases of thrombocytopenia caused 
by drugs, pseudothrombocytopenia, family history consistent 
with inherited thrombocytopenia, human immunodeficiency 
virus infection, and autoimmune disorders were excluded. 
Patients with hepatitis were included if they had normal 
liver function and the inactive virus. Two patients with 
lymphoma were included; one had complete response to 
lymphoma treatment at the time of participation and the 
other was simultaneously diagnosed with ITP and diffuse 
large B cell lymphoma. Patients were excluded if they had 
been treated for H. pylori within 2 years of recruitment 
or if they had been treated with an antibiotic or proton 
pump inhibitor within the previous 4 weeks.
2. Diagnosis and treatment
All 25 patients were screened for H. pylori infection using 
a 
13C-urea breath test (UBT), serum H. pylori antibody, or 
a rapid urease test (CLO test) by an endoscopic biopsy.
H. pylori infection was treated with standard eradication 
therapy: amoxicillin 1,000 mg twice daily, clarithromcin 500 
mg twice daily, and a proton pump inhibitor 40 mg twice 
daily for 1 or 2 weeks. 
  Platelet counts were assessed when patients reached re-
mission after H. pylori eradication therapy, and were again 
assessed long after the completion of eradication treatment. 
These platelet counts were compared with those taken at 
the baseline.
3. Response criteria
  T h e  c l i n i c a l  r e s p o n s e  t o  treatment was defined by the 
International Working Group on ITP [22]. Complete re-
sponse (CR) was defined as a platelet count of at least 
100×10
3/μL for more than 2 months with or without main-
tenance therapy. Partial response (PR) was defined as a plate-
let count of at least 30×10
3/μL and at least doubling the 
baseline count over a period of more than 2 months. No 
response (NR) was defined as a platelet count below 30× 
10
3/μL, or when the platelet count did not increase to more 
than 50% of the pretreatment level with or without main-
tenance therapy.
4. Statistical analysis
  Data are expressed as the median (range) as appropriate. 
The following variables were analyzed to identify factors 
associated with the improvement in the platelet count after 
eradication therapy: age, sex, disease duration, H. pylori in-
fectivity, duration of H. pylori eradication therapy, platelet 
count upon H. pylori eradication, platelet count at initial 
response, concomitant treatment with steroid, existence of 
peptic ulcer, hepatitis virus carrier, and survival. A chi-square 
or Fischer exact test was used for analysis of categorical 
data; the t test was used to compare groups in which the 
data involved continuous variables. A P-value of less than 
0.05 was considered statistically significant. Duration of re-
sponse after H. pylori eradication was graphed by the 
Kaplan-Meier method. All statistical analyses were per-
formed by using SPSS software version 15.0 (SPSS, Inc., 
Chicago, IL, USA).Korean J Hematol 2010;45:127-32.
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Fig. 1. Response duration after Helicobacter pylori eradication therapy 
in patients with idiopathic thrombocytopenic purpura (ITP). The 
median duration from response to relapse of ITP was 27.43 months 
(range, 2.0-116.9 months).
Table 2. Outcomes after H. pylori eradication.
Variables  
Platelet count after H. pylori 
eradication, μL,
 Median (range) 100,000
(46,000-172,000)
Duration from eradication to initial 
response, months  
Median (range) 3.10 (0.2-42.80)
Total response duration, 
months  
Median (range) 10.77 (0-116.9)
Response (%)
CR
PR 
NR 
11 (44.0)
6 (24.0)
8 (32.0)
Reinfection of H. pylori (%)
Yes 
No 
1 (4.0)
24 (96.0)
Relapse of ITP (%)
Yes 
No 
6 (24)
19 (76)
Duration from response to 
relapse, months
Median (range)  27.43 (2.0-116.90)
The values represent either the number (percentage) or the median
(range).
Abbreviations: H. pylori, Helicobacter pylori follow-up duration, 
from diagnosis of ITP to last follow-up date
RESULTS 
1. Patient characteristics
  Background characteristics of the patients with ITP are 
indicated in Table 1. The median age was 55 years (range: 
35-76 years), 18 were men (7 women), and the median plate-
let count was 78×10
3/μL (range: 6-96×10
3/μL). The median 
follow-up duration of this study was 57.57 months (range: 
4.53-123.53 months). Twenty-three patients had histologi-
cally confirmed H. pylori infection from UBT or CLO test. 
All patients experienced complete bacterial eradication. Of 
these patients, 2 had received immunosuppressive and an-
ti-RhD immunoglobulin treatment before H. pylori erad-
ication therapy. Underlying conditions included peptic ulcer 
in 18 patients (72%), and 16 patients (64%) were carriers 
of hepatitis B or C, all with low viral titers, and who were 
not receiving treatment of hepatitis. Of the 2 patients with 
malignant lymphoma, 1 had achieved CR before the start 
of  H. pylori eradication. The other patient was simulta-
neously diagnosed with ITP and lymphoma and experienced 
no platelet recovery after H. pylori eradication.
2. Platelet response to eradication therapy
  Outcomes after H. pylori eradication of the patients with 
ITP are indicated in Table 2. CR was obtained in 11 (44%) 
of the 25 patients, and a partial response in 6 (24%) patients, 
for an overall response rate (ORR) of 68%. Median follow-up 
duration was 57.57 months (range: 4.53-123.53 months) in 
this study. The median duration from eradication to initial 
response was 3.10 months (range: 0.2-42.8 months). H. pylori 
reinfection developed in 1 patient (4%) and ITP relapse 
developed in 6 patients (24%). The 1 H. pylori-reinfected 
patient also experienced an ITP relapse. The median duration 
from response to ITP relapse was 27.43 months (range: 
2.0-116.9 months). The response duration in patients under-
going H. pylori eradication is shown in Fig. 1. Individual 
changes in platelet counts in responsive, non-responsive and 
relapsed patients with complete eradication are shown in 
Fig. 2. 
3. Predictors of response
Predictors of response to H. pylori eradication therapy 
included platelet counts at the initial response (27.3% res-
ponders among patients with platelet counts ＜100×10
3/μL 
vs 100% responders among patients with platelet counts 
≥100×10
3/μL, P＜0.001) and H. pylori infectivity (73.9% 
responders among the H. pylori positive patients vs 0% res-
ponders among the H. pylori negative patients, P=0.032) 
(Table 3). Other tested factors did not differ significantly 
between the responders and nonresponders. The response 
rates differed with age and hepatitis virus carrier status but 
these differences were not statistically significant (hepatitis 
virus carrier [56.3%] vs none hepatitis virus carrier [88.9%] 
and ＜60 years [76.5%] vs. ≥60 years [50.0%]). One patient 
experienced relapse 2 months after H. pylori eradication 
therapy, and the patient’s platelet counts were restored by 
treatment with rituximab.
DISCUSSION 
  Many studies have shown an association between H. pylori 
infection and ITP, and substantial evidence has indicated 
that achieving H. pylori eradication can lead to a significant 
improvement in platelet counts in these H. pylori-positive Korean J Hematol 2010;45:127-32.
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ITP patients. 
  Gasbarrini et al. first reported that patients in whom  
H. pylori infection was eradicated showed significant in-
creases in platelet count with the disappearance of anti-plate-
let antibodies [23]. Emilia et al. [16] reported that H. pylori 
eradicated ITP patients exhibited a significant increase in 
platelet count. Several studies on the H. pylori eradication 
therapy in Japan and Korea have documented similarly favor-
able results. Inaba, Sato, Kohda, Suzuki, and Song et al. 
demonstrated a favorable platelet response in patients in 
whom H. pylori was successfully eradicated [13-15, 17, 24]. 
The results of our study were comparable to those of previous 
studies and suggested the long-term efficacy of H. pylori 
eradication therapy in patients with H. pylori infection and 
ITP. The prevalence of H. pylori infection in the ITP patients 
in this study was 92%. A CR was obtained in 44%, with 
a PR obtained in 24%, for an ORR of 68%. These favorable 
results may be associated with more of our patients having 
baseline platelet counts of more than 30×10
3/μL and fewer 
patients having undergone prior treatment for ITP. We ob-
served a median 27.43-months duration of response after 
H. pylori eradication (range: 2.0-116.9 months). In compar-
ison with other studies, there were no remarkable differences 
in the median duration of responders ranging from 4 to 
43.5 months [25].
  In contrast to our study, an Italian report by Stasi et al. 
concluded that H. pylori eradication therapy had no favorable 
effect on patients with ITP [18]. Ahn and Suvajdzić et al. 
also described a poor response to H. pylori eradication ther-
apy in patients with ITP in the United States and the United 
Kingdom, respectively [19, 20]. 
  The platelet recovery rate after H. pylori eradication ther-
apy appears to be as heterogeneous between studies as the 
response rates. In most studies, a shorter ITP duration is 
correlated with better chance of response [18, 26]. In one 
study, a complete response was associated with no prior 
prednisone therapy [27]. The presence of the HLA-DQB1*03 
allele has also been associated with higher response rates 
[12]. There are conflicting reports about the predictive value 
of some characteristics such as age and baseline platelet count 
[13, 16, 17, 20]. Our study revealed that after H. pylori 
eradication both high platelet counts (more than 100×10
3/μL) 
at the initial response and the presence of H. pylori infection 
predicted better platelet recovery. However, no significant 
difference in the response rate with age or hepatitis virus 
carrier status was noted between the responders and non-
responders. There have been some questions about the associ-
ation between hepatitis C and autoimmune thrombocytopenia. 
Fig. 2. Individual changes of platelet counts in responsive, non- 
responsive and relapsed patients with complete Helicobacter pylori 
(H. pylori) eradication were shown. Time course of platelet counts 
after H. pylori eradication therapy in responsive patients (A), non-
responsive patients (B), and relapsed patients (C). In Fig. 1(C), 1 
patient relapsed at 2 months after H. pylori eradication therapy and 
then platelet counts recovered after treatment with rituximab. Korean J Hematol 2010;45:127-32.
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Table 3. Comparison of the patients characteristics between responders and non-responders.
Variable (number) Responders (n=17) Non-responders (n=8) P
Age, years (%)
<60 (17)
≥60 (8)
13 (76.5)
4 (50)
4 (23.5)
4 (50)
0.359
Sex (%)
Male (18)
Female (7)
11 (61.1)
6 (85.7)
7 (38.9)
1 (14.3)
0.236
Disease duration (%)
<3 months (13)
≥3 months (12)
9 (69.2)
4 (30.8)
8 (66.7)
4 (33.3)
0.891
Disease duration, months
Mean±SD 5.08±5.75 9.66±10.92 0.294
H. pylori infectivity (%)
Positive (23)
Negative (2)
17 (73.9)
0 (0)
6 (26.1)
2 (100)
0.032
Duration of H. pylori eradication (%)
7 days (21)
14 days (4)
15 (71.4)
2 (50.0)
6 (28.6)
2 (50.0)
0.400
Platelet count at H. pylori eradication (%)
<30,000/μL (2)
≥30,000/μL (23)
2 (100.0)
15 (65.2)
0 (0)
8 (34.8)
0.312
Platelet count at H. pylori eradication, /μL 
Mean±SD 69,294.1±25,733.6 67,375±20,416.6 0.855
Duration from H. pylori Tx to initial response, months
Mean±SD 6.3882±10.212 6.4250±9.247 0.993
Platelet count at initial response (%)
＜100,000/μL (11)
≥100,000/μL (14)
3 (27.3)
14 (100.0)
8 (72.7)
0 (0)
0.000
Concomittent Tx with steroid (%)
Yes (1)
No (24) 
1 (100)
16 (68.0)
0 (0)
8 (33.3)
0.484
Existence of peptic ulcer (%)
Yes (18)
No (6)
No test (1)
12 (66.7)
4 (66.7)
1 (100)
6 (33.3)
2 (33.3)
0 (0)
0.783
Hepatitis virus carrier (%)
Yes (16) 
No (9)
9 (56.3)
8 (88.9)
7 (43.8)
1 (11.1)
0.182
The values represent either the number (percentage) or the mean±SD.
Abbreviations: H. pylori, Helicobacter pylori; PLT, platelet; Tx, treatment.
Panzer et al. suggested that thrombocytopenia in patients 
with hepatitis C infection may be due to a variety of non-
immune and immune mechanisms [28]. In our study, hep-
atitis carriers exhibited poorer platelet recovery rates than 
noncarriers, indicating that other mechanisms may be asso-
ciated with the poor response rate in ITP patients who are 
hepatitis carriers. On the basis of a previous report that 
suggests lymphoma has the same mechanism of platelet de-
struction as primary ITP infection [29]. 2 patients with lym-
phoma were included in this study to determine whether 
their H. pylori infection possibly influenced a reduction of 
their platelet counts. One patient was responsive to the treat-
ment whereas the other was not.
  In conclusion, the eradication of H. pylori in ITP patients 
was effective in restoring platelet counts in patients at one 
institute in South Korea. A higher platelet count (＞100× 
10
3/μL at initial response) and the presence of H. pylori 
infection were associated with platelet recovery after H. 
pylori eradication therapy. Further studies are required to 
clarify other causative factors involved in platelet recovery, 
monitor the duration of response, and understand the mecha-
nism underlying the response to eradication therapy.  
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